翰森制药集团有限公司（03692）于2026年2月3日公告的截至2026年1月31日股份变动月报显示，公司在本月内股本结构没有发生变化，整体股本维持稳定。
公司注册股本为20,000,000,000股普通股，面值每股HKD0.00001，总额HKD200,000。至1月末，已发行股份总数为6,055,150,070股，与上月底相同，期间无新增发行、购回或注销股份，亦无库藏股份变动。
公司此前发行的于2026年到期的零息可换股债券（余额USD5,378,000）已于本月到期并归零，本月内未因此新增发行股份或转让库藏股份。截至1月末，公司符合香港联交所关于最低公众持股量的相关要求。
本月报由联席公司秘书钟胜利女士签署。公司确认其遵守香港联交所上市规则及相关法律规定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.